文献速递炎症性肠病

早期COVID-19大流行期间炎症性肠病发作患者的治疗调整与结局:PREPARE-IBD多中心队列研究

Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study.
PubMed 文献 · Aliment Pharmacol Ther · 2022-10-05

该多中心观察性队列研究纳入2020年3月至6月英国60家国民健康服务信托机构中因症状发作联系炎症性肠病团队的1864例患者,并与倾向性匹配的流行前队列比较。结果显示大流行期间全身性皮质类固醇处方减少,生物制剂使用增加,但3个月无类固醇缓解率与流行前相似;同时出现发作和疑似COVID-19的患者3个月时疾病活动度更高。

要点

  • 大流行期间克罗恩病泼尼松龙处方率为26.5% vs 流行前37.1%(p<0.001),溃疡性结肠炎为33.5% vs 40.7%(p<0.001)。
  • 大流行期间生物利用度差的口服皮质类固醇在克罗恩病为15.6% vs 6.8%(p<0.001),溃疡性结肠炎为11.8% vs 5.2%(p<0.001)。
  • 3个月无类固醇缓解率克罗恩病28.4% vs 32.1%(p=0.17),溃疡性结肠炎36.4% vs 40.2%(p=0.095)。

核心结论

  • 尽管大流行期间进行了治疗调整,无类固醇结局与流行前水平相当,但同时出现发作和疑似COVID-19导致更差的结局。

研究设计与样本

  • 多中心观察性队列研究,纳入2020年3月至6月英国60家国民健康服务信托机构中因症状发作联系炎症性肠病团队的患者,并与倾向性匹配年龄和医生整体疾病活动度评估的流行前队列比较;每个队列各1864例患者。

主要发现

  • 克罗恩病全身性泼尼松龙处方在大流行期间为26.5% vs 流行前37.1%(p<0.001)。
  • 溃疡性结肠炎全身性泼尼松龙处方在大流行期间为33.5% vs 流行前40.7%(p<0.001)。
  • 克罗恩病生物利用度差的口服皮质类固醇在大流行期间为15.6% vs 流行前6.8%(p<0.001)。
  • 溃疡性结肠炎生物利用度差的口服皮质类固醇在大流行期间为11.8% vs 流行前5.2%(p<0.001)。
  • 乌司奴单抗(克罗恩病和溃疡性结肠炎)和维得利珠单抗(溃疡性结肠炎)治疗也显著增加。

关键数值与推荐

  • 3个月无类固醇缓解率在克罗恩病为大流行期间28.4% vs 流行前32.1%(p=0.17)。
  • 3个月无类固醇缓解率在溃疡性结肠炎为大流行期间36.4% vs 流行前40.2%(p=0.095)。
  • 同时出现发作和疑似COVID-19的患者在3个月时更可能具有中度至重度活动性疾病。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The COVID-19 pandemic offered a unique opportunity to understand inflammatory bowel disease (IBD) management during unexpected disruption. This could help to guide practice overall. AIMS: To compare prescribing behaviour for IBD flares and outcomes during the early pandemic with pre-pandemic findings METHODS: We performed an observational cohort study comprising patients who contacted IBD teams for symptomatic flares between March and June 2020 in 60 National Health Service trusts in the United Kingdom. Data were compared with a pre-pandemic cohort after propensity-matching for age and physician global assessment of disease activity. RESULTS: We included 1864 patients in each of the pandemic and pre-pandemic cohorts. The principal findings were reduced systemic corticosteroid prescription during the pandemic in Crohn's disease (prednisolone: pandemic 26.5% vs. 37.1%; p < 0.001) and ulcerative colitis (UC) (prednisolone: pandemic 33.5% vs. 40.7%, p < 0.001), with increases in poorly bioavailable oral corticosteroids in Crohn's (pandemic 15.6% vs. 6.8%; p < 0.001) and UC (pandemic 11.8% vs. 5.2%; p < 0.001). Ustekinumab (Crohn's and UC) and vedolizumab (UC) treatment also significantly increased. Three-month steroid-free remission in each period was similar in Crohn's (pandemic 28.4% vs. 32.1%; p = 0.17) and UC (pandemic 36.4% vs. 40.2%; p = 0.095). Patients experiencing a flare and suspected COVID-19 were more likely to have moderately-to-severely active disease at 3 months than those with a flare alone. CONCLUSIONS: Despite treatment adaptations during the pandemic, steroid-free outcomes were comparable with pre-pandemic levels, although concurrent flare and suspected COVID-19 caused worse outcomes. These findings have implications for IBD management during future pandemics and for standard practice.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Saifuddin A, Kent AJ, Mehta SJ, et al. Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study. Aliment Pharmacol Ther. 2022. PMID: 36196569. doi:10.1111/apt.17223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。